{"public_id":"cl_337767d435ab802329833c4112d4ec77","status":"active","superseded_by_public_id":null,"corpus_id":207577951,"text":"Mean pirfenidone exposure in RECAP was 122 weeks, median exposure was 88 weeks, and cumulative exposure reached 2,482 patient exposure years.","confidence":0.95,"paper":{"corpus_id":207577951,"title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","url":"https://sah.borca.ai/papers/207577951"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_19febba12894bfb98417cc99d7df6167","name":"patient exposure years","description":"A measure of cumulative treatment exposure expressed as the number of patients observed for one year.","types":["measurement"],"url":"https://sah.borca.ai/concepts/co_19febba12894bfb98417cc99d7df6167"},{"public_id":"co_7409daee74d4701ab4dfd47abdcc218f","name":"pirfenidone","description":"An antifibrotic drug evaluated here for long-term safety in idiopathic pulmonary fibrosis.","types":["drug","treatment"],"url":"https://sah.borca.ai/concepts/co_7409daee74d4701ab4dfd47abdcc218f"},{"public_id":"co_bb2628c3df9c561b3f862768f2fd8216","name":"RECAP","description":"An open-label extension study that followed patients with idiopathic pulmonary fibrosis who had completed prior pirfenidone phase 3 trials.","types":["clinical study","open-label extension study"],"url":"https://sah.borca.ai/concepts/co_bb2628c3df9c561b3f862768f2fd8216"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_337767d435ab802329833c4112d4ec77"}